Scarica l'app Stockscreener
34.40
0.32%
0.11
Dopo l'orario di chiusura:
34.40
Precedente Chiudi:
$34.29
Aprire:
$34.48
Volume 24 ore:
296.38K
Relative Volume:
0.55
Capitalizzazione di mercato:
$963.10M
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-5.6579
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+8.28%
1M Prestazione:
+77.32%
6M Prestazione:
+80.48%
1 anno Prestazione:
-0.84%
Intervallo 1D:
$33.85
$35.77
Intervallo di 1 settimana:
$31.18
$35.77
Portata 52W:
$12.21
$36.54
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
34.40 | 890.94M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Trading Systems Reacting to (ANAB) Volatility - news.stocktradersdaily.com
ANAB: Wedbush Raises Price Target Amidst Outperform Rating | ANAB Stock News - GuruFocus
AnaptysBio stock holds Buy rating at H.C. Wainwright after CD122 inhibitor webinar - Investing.com Canada
Can AnaptysBio Inc. stock beat market expectations this quarterQuarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
AnaptysBio, Inc. Updates on ANB033 and Corporate Developments - TradingView
Barclays Initiates Coverage on AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio stock price target raised to $72 from $57 at Piper Sandler - Investing.com
How AnaptysBio Inc. stock reacts to job market dataQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Rosnilimab phase 2b rheumatoid arthritis data to be presented at ACR - Investing.com Nigeria
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 - MarketScreener
Why AnaptysBio Inc. stock could outperform in 2025July 2025 Reactions & Technical Pattern Alert System - newser.com
Should you wait for a breakout in AnaptysBio Inc.Weekly Gains Report & Verified Momentum Stock Alerts - newser.com
AnaptysBio Announces Late-Breaking Presentation of Phase 2b Trial Data for Rosnilimab in Rheumatoid Arthritis at ACR Convergence 2025 - Quiver Quantitative
Anaptys Announces Late-Breaking Oral Presentation of - GlobeNewswire
AnaptysBio to present rosnilimab rheumatoid arthritis data at ACR meeting - StreetInsider
6‑Month JAK‑like Efficacy: Anaptys' Rosnilimab Phase 2b Accepted for ACR Late‑Breaking Oral Presentation - Stock Titan
Barclays Initiates Coverage on AnaptysBio (ANAB) with Overweight Rating | ANAB Stock News - GuruFocus
Barclays Initiates AnaptysBio at Overweight With $78 Price Target - MarketScreener
AnaptysBio Inc. stock prediction for this weekQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Barclays initiates AnaptysBio stock with Overweight rating on rosnilimab potential - Investing.com Canada
What drives AnaptysBio Inc stock priceMarket Depth Overview & Small Investment Capital Tips - earlytimes.in
How moving averages guide AnaptysBio Inc. tradingGold Moves & Risk Managed Investment Signals - newser.com
Q3 EPS Estimates for AnaptysBio Lifted by Leerink Partnrs - MarketBeat
Can AnaptysBio Inc. (AN6) stock resist broad market declinesWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarks2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
AnaptysBio splits operations into two companies - MSN
AnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HighMark Wealth Management LLC Raises Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for AnaptysBio - MarketBeat
Custom strategy builders for tracking AnaptysBio Inc.Market Sentiment Report & Growth Focused Stock Reports - newser.com
Is AnaptysBio Inc. reversing from oversold territoryWeekly Trade Review & Daily Chart Pattern Signals - newser.com
Applying sector rotation models to AnaptysBio Inc.2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Chart overlay techniques for tracking AnaptysBio Inc.July 2025 Short Interest & Safe Capital Growth Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingEarnings Miss & Breakout Confirmation Alerts - newser.com
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9%Time to Sell? - MarketBeat
HC Wainwright Analysts Cut Earnings Estimates for AnaptysBio - MarketBeat
Biggest stock movers today: UUUU, FLY, and more - MSN
AnaptysBio (NASDAQ:ANAB) Trading 8.9% Higher After Analyst Upgrade - Defense World
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Shares Up 8.9% on Analyst Upgrade - MarketBeat
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):